ATE445646T1 - Humaner miniantikörper zytotoxisch für tumorzellen die den erbb2 rezeptor exprimieren - Google Patents

Humaner miniantikörper zytotoxisch für tumorzellen die den erbb2 rezeptor exprimieren

Info

Publication number
ATE445646T1
ATE445646T1 AT02784853T AT02784853T ATE445646T1 AT E445646 T1 ATE445646 T1 AT E445646T1 AT 02784853 T AT02784853 T AT 02784853T AT 02784853 T AT02784853 T AT 02784853T AT E445646 T1 ATE445646 T1 AT E445646T1
Authority
AT
Austria
Prior art keywords
express
tumor cells
erbb2 receptor
human mini
erbb2
Prior art date
Application number
AT02784853T
Other languages
English (en)
Inventor
Alessio Giuseppe D
Renata Piccoli
Lorenzo Claudia De
Donald Balfour Palmer
Mary Alice Ritter
Original Assignee
Biotecnol Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotecnol Sa filed Critical Biotecnol Sa
Application granted granted Critical
Publication of ATE445646T1 publication Critical patent/ATE445646T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02784853T 2001-07-10 2002-07-10 Humaner miniantikörper zytotoxisch für tumorzellen die den erbb2 rezeptor exprimieren ATE445646T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001RM000408A ITRM20010408A1 (it) 2001-07-10 2001-07-10 Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2.
PCT/EP2002/007671 WO2003006509A2 (en) 2001-07-10 2002-07-10 Human mini-antibody cytotoxic for tumor cells which express the erbb2 receptor

Publications (1)

Publication Number Publication Date
ATE445646T1 true ATE445646T1 (de) 2009-10-15

Family

ID=11455653

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02784853T ATE445646T1 (de) 2001-07-10 2002-07-10 Humaner miniantikörper zytotoxisch für tumorzellen die den erbb2 rezeptor exprimieren

Country Status (13)

Country Link
US (2) US7585952B2 (de)
EP (1) EP1432737B1 (de)
AT (1) ATE445646T1 (de)
CA (1) CA2453435A1 (de)
DE (1) DE60234041D1 (de)
DK (1) DK1432737T3 (de)
ES (1) ES2334895T3 (de)
IT (1) ITRM20010408A1 (de)
NZ (1) NZ531035A (de)
PT (1) PT1432737E (de)
SI (1) SI1432737T1 (de)
WO (1) WO2003006509A2 (de)
ZA (1) ZA200401044B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITFI20010114A1 (it) * 2001-06-22 2002-12-22 Univ Firenze Glicopeptidi,loro preparazione e loro uso nella diagnosi o nel trattamento terapeutico della sclerosi multipla
CN102580084B (zh) 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
EP1850874B1 (de) 2005-02-23 2013-10-16 Genentech, Inc. Verzögerung des krankheitsverlauf bei eierstockkrebspatienten durch pertuzumab
US20100015661A1 (en) * 2006-04-21 2010-01-21 Mab-Factory Gmbh Antibody-rnase-conjugate
US8350011B2 (en) * 2006-08-04 2013-01-08 Medimmune Limited Antibodies to ErbB2
SI2132573T1 (sl) 2007-03-02 2014-07-31 Genentech, Inc. Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
PL2171090T3 (pl) 2007-06-08 2013-09-30 Genentech Inc Markery ekspresji genów odporności guza na leczenie hamujące HER2
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
MY152068A (en) 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
CN102421448A (zh) 2009-05-29 2012-04-18 霍夫曼-拉罗奇有限公司 Her2信号传导调控剂在表达her2的胃癌患者中
US9556249B2 (en) 2010-02-18 2017-01-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
CA3255551A1 (en) 2010-03-26 2025-04-15 Memorial Sloan-Kettering Cancer Center MUC16 ANTIBODIES AND METHODS OF USE
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
US20120148559A1 (en) 2010-12-01 2012-06-14 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
MX2014001766A (es) 2011-08-17 2014-05-01 Genentech Inc Anticuerpos de neuregulina y sus usos.
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
BR112014012979A2 (pt) 2011-11-30 2020-10-20 Genentech, Inc. mutações erbb3 em câncer
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
US20130259867A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
KR102291355B1 (ko) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
US9738726B2 (en) 2013-06-11 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HER2-specific monoclonal antibodies and conjugates thereof
US10155028B2 (en) 2013-08-26 2018-12-18 Health Research, Inc. Method for prophylaxis and/or treatment of ErbB2 positive cancers
SG11201608192SA (en) 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
EA035419B9 (ru) 2014-05-29 2020-08-07 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы и способы их применения
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
US10478477B2 (en) 2014-08-20 2019-11-19 Health Research, Inc. Method for prophylaxis or treatment of erbb1 positive cancers using a variant peptidase d with reduced activity
MX375669B (es) 2014-09-26 2025-03-06 Macrogenics Inc Diacuerpos monovalentes biespecificos que son capaces de unir cd19 y cd3, y usos de los mismos.
SG11201707538XA (en) 2015-03-17 2017-10-30 Memorial Sloan Kettering Cancer Center Anti-muc16 antibodies and uses thereof
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07309780A (ja) * 1994-03-02 1995-11-28 N Bii T Kk 抗癌剤
US5795961A (en) * 1995-02-14 1998-08-18 Ludwig Institute For Cancer Research Recombinant human anti-Lewis b antibodies
GB9805660D0 (en) * 1998-03-18 1998-05-13 Unichema Chemie Bv Improvements in and relating to fatty acid metabolism
US6135941A (en) 1998-03-27 2000-10-24 Incyte Pharmaceuticals, Inc. Human immune system associated molecules
US6794128B2 (en) 1998-04-24 2004-09-21 The Regents Of The University Of California Methods of selecting internalizing antibodies
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
WO2001014558A1 (en) * 1999-08-26 2001-03-01 Morphosys Ag Human antibodies or fragments thereof binding to hla-cw6
WO2001027279A1 (en) 1999-10-12 2001-04-19 Cambridge Antibody Technology Human anti-adipocyte monoclonal antibodies and their use

Also Published As

Publication number Publication date
DK1432737T3 (da) 2010-02-08
EP1432737B1 (de) 2009-10-14
WO2003006509A2 (en) 2003-01-23
SI1432737T1 (sl) 2010-02-26
NZ531035A (en) 2005-04-29
ZA200401044B (en) 2004-10-22
WO2003006509A3 (en) 2003-11-20
US20100173978A1 (en) 2010-07-08
CA2453435A1 (en) 2003-01-23
ITRM20010408A1 (it) 2003-01-10
ES2334895T3 (es) 2010-03-17
ITRM20010408A0 (it) 2001-07-10
DE60234041D1 (de) 2009-11-26
EP1432737A2 (de) 2004-06-30
US7585952B2 (en) 2009-09-08
PT1432737E (pt) 2010-02-17
US20070258985A1 (en) 2007-11-08
US8227585B2 (en) 2012-07-24

Similar Documents

Publication Publication Date Title
ATE445646T1 (de) Humaner miniantikörper zytotoxisch für tumorzellen die den erbb2 rezeptor exprimieren
MY154009A (en) Anti-alpha v beta 6 antibodies
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
BE2016C015I2 (de)
UA87804C2 (ru) Моноклональное антитело человека, которое специфически связывается с рецептором инсулиноподобного фактора роста і (igf-ir)
WO2004001381A3 (en) Novel raag10 cell surface target and a family of antibodies recognizing that target
IL129299A0 (en) Monoclonal antibodies antigens and diagnosis of malignant diseases
WO2004029092A3 (fr) Anticorps pour adcc et induisant la production de cytokines.
NZ600584A (en) Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof
TR200102733T2 (tr) IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri
WO2005012493A3 (en) Anti-cd19 antibodies
GEP20074222B (en) Antibodies to cd40
AU2003215188A8 (en) Fusion proteins of humanized g250 specific antibodies and uses thereof
EP1187591A4 (de) Mit entzündlichen darmerkrankungen (ibd) assoziierte mikrobielle antigene und verfahren derer anwendung
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
CA2469833A1 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
PE20070374A1 (es) ANTICUERPOS ANTI-MAdCAM
SG146644A1 (en) Kid3 and kid3 antibodies that bind thereto
WO2004108766A3 (en) Anti-hgf-r antibodies and their use
WO2006084078A3 (en) Jam-3 and antibodies that bind thereto
MX2007000103A (es) Bibliotecas de anticuerpos universales.
ZA200508389B (en) Humanized antibodies to interferon alpha receptor-1(IFNAR-1)
WO2004043239A3 (en) Antigen pipa and antibodies that bind thereto
WO2006083852A3 (en) Luca2 and antibodies that bind thereto
ATE435283T1 (de) Isolierte, für krebs-assoziierte antigene kodierende nukleinsäuremoleküle, die antigene per se und deren anwendungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1432737

Country of ref document: EP